Quarterly report pursuant to Section 13 or 15(d)

IN-LICENSING AND ACQUISITION - Narrative (Details)

v3.24.3
IN-LICENSING AND ACQUISITION - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 22, 2024
Jul. 31, 2024
Jul. 27, 2022
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2023
Asset Acquisition [Line Items]                    
Acquisition-related liabilities       $ 5,000     $ 5,000      
Research and development       6,182 $ 6,475   17,748 $ 21,336    
Intangible asset       27,687     $ 27,687     $ 13,878
Forma                    
Asset Acquisition [Line Items]                    
Upfront fee     $ 2,000              
Research and development                 $ 2,000  
Forma | Commercial milestones                    
Asset Acquisition [Line Items]                    
Potential payments     165,500              
Forma | Development and regulatory milestones                    
Asset Acquisition [Line Items]                    
Potential payments     $ 67,500              
Forma | Achievement of certain near-term regulatory milestone                    
Asset Acquisition [Line Items]                    
Research and development           $ 2,500        
GAVRETO (pralsetinib)                    
Asset Acquisition [Line Items]                    
Intangible assets, estimated useful life             12 years      
REZLIDHIA                    
Asset Acquisition [Line Items]                    
Intangible assets, estimated useful life             14 years      
REZLIDHIA | Forma | FDA approval and first commercial sale of product                    
Asset Acquisition [Line Items]                    
Intangible asset           $ 15,000     $ 15,000  
Blueprint                    
Asset Acquisition [Line Items]                    
Acquisition payment $ 15,000                  
Asset purchase agreement, drug product inventories       6,500     $ 6,500      
Blueprint | GAVRETO (pralsetinib)                    
Asset Acquisition [Line Items]                    
Asset acquisition, expected price $ 15,000                  
Acquisition-related liabilities       $ 5,000     $ 5,000      
Acquisition payment   $ 10,000                
Blueprint | GAVRETO (pralsetinib) | Minimum                    
Asset Acquisition [Line Items]                    
Potential tiered royalties (as a percentage) 10.00%                  
Blueprint | GAVRETO (pralsetinib) | Maximum                    
Asset Acquisition [Line Items]                    
Potential tiered royalties (as a percentage) 30.00%                  
Blueprint | GAVRETO (pralsetinib) | First commercial sale                    
Asset Acquisition [Line Items]                    
Asset acquisition, expected price $ 10,000                  
Blueprint | GAVRETO (pralsetinib) | First anniversary of the closing date                    
Asset Acquisition [Line Items]                    
Asset acquisition, expected price 5,000                  
Blueprint | GAVRETO (pralsetinib) | Commercial milestones                    
Asset Acquisition [Line Items]                    
Potential milestone payments 97,500                  
Blueprint | GAVRETO (pralsetinib) | Regulatory milestones                    
Asset Acquisition [Line Items]                    
Potential milestone payments $ 5,000